Abstract
The kinase inhibitor gedatolisib (Revtorpyk – Celcuity) has been approved by the FDA for use in combination with fulvestrant, with or without the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (Ibrance), for treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation in adults who had disease progression on or after at least one prior line of endocrine therapy for metastatic disease.